EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

Sitbon, Olivier; Delcroix, Marion; Bergot, Emmanuel; Boonstra, Anco B; Granton, John; Langleben, David; Subías, Pilar Escribano; Galiè, Nazzareno; Pfister, Thomas; Lemarié, Jean-Christophe; Simonneau, Gérald

doi:10.1016/j.ahj.2013.08.007

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension

Author:

Sitbon, Olivier

Delcroix, Marion ; Bergot, Emmanuel ; Boonstra, Anco B ; Granton, John ; Langleben, David ; Subías, Pilar Escribano ; Galiè, Nazzareno ; Pfister, Thomas ; Lemarié, Jean-Christophe ; Simonneau, Gérald

Keywords:

Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, NATRIURETIC PEPTIDE, TREPROSTINIL, PROSTACYCLIN, SODIUM, Adult, Aged, Antihypertensive Agents, Cardiac Catheterization, Dose-Response Relationship, Drug, Epoprostenol, Exercise Tolerance, Familial Primary Pulmonary Hypertension, Female, Follow-Up Studies, Hemodynamics, Humans, Hypertension, Pulmonary, Infusions, Intravenous, Male, Middle Aged, Patient Satisfaction, Prospective Studies, Single-Blind Method, Surveys and Questionnaires, Treatment Outcome, Young Adult, 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology

Abstract:

Continuous infusion of epoprostenol is the treatment of choice in patients with pulmonary arterial hypertension in functional classes III to IV. However, this treatment's limitations include instability at room temperature. A new epoprostenol formulation offers improved storage conditions and patient convenience.